About this trial
This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering Shenque, Zhongguo, Guanyuan, and Qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients were fully aware of the study, participated voluntarily, and signed the informed consent form;
Age: 18-55 years old;
patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation;
Disqualifiers
refusal to participate in this clinical study;
broken or sensitized skin corresponding to the moxibustion site;
allogeneic hematopoietic stem cell transplantationpatients pretreated with the Reduced-intensity conditioning.
Trial design
Single group
Treatments tested in this trial
Moxibustion
Other interventionSubjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
Symptomatic supportive treatment
Other interventionSymptomatic supportive treatment.
Treatment groups
Trial outcomes
Primary outcomes
Core Lower Urinary Tract Symptom Score
The Core Lower Urinary Tract Symptom Score consists of 10 questions. Frequent daytime urination---0 points:\<7 times;1 point:8\~9 times;2 points:10\~14 times;3 points:\> 14 times. Nocturia---0 points:0 times/night;1 point:1 time/night;2 points: 2\~3 times/night;3 points:\> 3 times/night. The other 8 problems were urgency, dysuria, hesitancy, thin urine line, urge incontinence, stress incontinence, bladder pain, and urethral pain, which were rated as 0, 1, 2, and 3 according to their frequency (never, rarely, sometimes, and often).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.